Ribavirin
ریباویرین
🦠 Antiinfectives For Systemic UseNucleoside analogue antiviral
Market / country: 🇺🇸 USA
Rebetol (US)
🧮 Dose calculator
Chronic hepatitis C · Regimen source: FDA Ribavirin caps · 2.2FDA Ribavirin caps · 2.3FDA Ribavirin caps · 2.1FDA Ribavirin caps · 2.5
🛡️ Safety & information
Contraindications
- ⛔ Pregnancy and male partners of pregnant women; haemoglobinopathies (thalassaemia major, sickle-cell); autoimmune hepatitis; decompensated liver disease; CrCl <50; didanosine. FDA Ribavirin caps · 4
Warnings
- • Boxed warning: severe embryo-fetal toxicity (contraception until 6 months after treatment for women and men); haemolytic anaemia; ineffective alone. FDA Ribavirin caps · Boxed Warning
Formulations
- 200 mg capsule — capsule 🇺🇸 USA FDA Ribavirin caps · 3
👥 Special populations
- 🤰 PregnancyContraindicated
Label: contraindicated in pregnancy. FDA Ribavirin caps · 4
“Ribavirin capsules combination therapy is contraindicated in: pregnancy.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Ribavirin caps · 8.2
“Risk Summary There are no data on the presence of ribavirin in human milk or the effects on the breastfed infant or milk production.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Ribavirin caps · 8.4
“Safety and effectiveness of ribavirin in combination with PegIntron has not been established in pediatric patients below the age of 3 years.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Ribavirin caps · 8.5
“In general, ribavirin capsules should be administered to elderly patients cautiously, starting at the lower end of the dosing range, reflecting the greater frequency of decreased hepatic and cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Ribavirin caps · 8.3
“Contraception Female patients of reproductive potential should use effective contraception during treatment and for 9 months post-therapy.”
🔗 Reference links
- FDA (approval record)ANDA079117
- DailyMed (FDA label)FDA Ribavirin caps
- MedlinePlus (NIH)Ribavirin
- WHO ATC/DDDJ05AP01
- Darooyab (Iran)Ribavirin
🇮🇷 Registered in Iran Darooyab · G-1199/Ribavirin
Dosage forms with Iranian generic codes, per Darooyab.
- 20076 · RIBAVIRIN 100MG AMP · آمپول ریباویرین ۱۰۰ میلیگرم
- 01879 · RIBAVIRIN 100MG CAP · کپسول ریباویرین ۱۰۰ میلیگرم
- 01880 · RIBAVIRIN 100MG TAB · قرص ریباویرین ۱۰۰ میلیگرم
- 01891 · RIBAVIRIN 200MG CAP · کپسول ریباویرین ۲۰۰ میلیگرم
- 01881 · RIBAVIRIN 200MG TAB · قرص ریباویرین ۲۰۰ میلیگرم
- 52656 · RIBAVIRIN TABLET ORAL 600 mg · قرص ریباویرین ۶۰۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Ribavirin caps · 3FDA Ribavirin caps · 2.2FDA Ribavirin caps · 2.3FDA Ribavirin caps · 2.1FDA Ribavirin caps · 2.5FDA Ribavirin caps · 4FDA Ribavirin caps · Boxed WarningFDA Ribavirin caps · SPL approval / marketing categoryFDA Ribavirin caps · 8.2FDA Ribavirin caps · 8.4FDA Ribavirin caps · 8.5FDA Ribavirin caps · 8.3
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-1199/Ribavirin
- Clinical review⚠ Unverified